Gain Therapeutics, Inc. (GANX) Financials
GANX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 18.7 million | 4.7 million |
| Dec. 31, 2025 | 22.8 million | 4.3 million |
| Sept. 30, 2025 | 11.0 million | 5.1 million |
| June 30, 2025 | 9.8 million | 6.1 million |
GANX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -4.7 million | 403509 |
| Dec. 31, 2025 | -4.6 million | 401667 |
| Sept. 30, 2025 | -4.9 million | 460005 |
| June 30, 2025 | -5.1 million | 522019 |
GANX Net Income
No data available :(
GANX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 16.5 million | 182129 | 298756 |
| Dec. 31, 2025 | 20.8 million | 300084 | 211238 |
| Sept. 30, 2025 | 8.8 million | 298797 | 180936 |
| June 30, 2025 | 6.7 million | 325359 | 229171 |
GANX Shares Outstanding
GANX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | 3 | 2.8 million | 2.6 million | -12303 |
| Dec. 31, 2025 | 3 | 2.3 million | 2.1 million | - |
| Sept. 30, 2025 | - | 2.8 million | 1.9 million | - |
| June 30, 2025 | - | 3.3 million | 2.4 million | 51433 |
GANX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 21303 |
| Dec. 31, 2025 | - | -4.9 million |
| Sept. 30, 2025 | - | 22817 |
| June 30, 2025 | - | 2.7 million |
GANX
Price: $1.88
52 week price:
Earnings Per Share: -0.58 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 17900
Market Capitalization: 76.4 million